89bio
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 70
- Market Cap
- $968M
- Website
- http://www.89bio.com
Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)β’ Click on a phase to view related trials
Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis)
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensated Cirrhosis
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- 89bio Inc.
- Target Recruit Count
- 155
- Registration Number
- 2023-510395-31-00
- Locations
- π¬π§
89bio Clinical Study Site, Southampton, United Kingdom
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
- Interventions
- Other: Placebo
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 1050
- Registration Number
- NCT06318169
- Locations
- π¬π§
89bio Clinical Study Site, York, United Kingdom
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT05852431
- Locations
- π¬π§
89bio Clinical Study Site, Cardiff, United Kingdom
π΅π·89Bio Clinical Study Site, San Juan, Puerto Rico
π±π»89bio Clinical Trial Site, Riga, Latvia
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05022693
- Locations
- πΊπΈ
89bio Clinical Study Site, Chandler, Arizona, United States
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT04929483
- Locations
- π΅π·
89bio Clinical Study Site, San Juan, Puerto Rico
- Prev
- 1
- 2
- Next
News
NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies
β’ The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. β’ This growth is fueled by the introduction of novel therapies targeting NASH, with several drugs in Phase II and Phase III clinical trials showing promise for improving treatment outcomes. β’ Key players such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Novo Nordisk are actively developing innovative treatments, contributing to a dynamic and competitive market landscape. β’ The increasing prevalence of NASH and the growing understanding of its pathophysiology are driving the demand for effective therapies, creating opportunities for pharmaceutical companies.